Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly director Gabrielle Sulzberger reported acquiring 4.668 shares of the company’s common stock on 12/15/2025 at $1,062.19 per share in an insider transaction. Following this transaction, she beneficially owns 2,956.674 shares directly.
The shares were acquired by deferring cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after her separation from service.
Eli Lilly & Co director Juan R. Luciano reported acquiring 13.965 shares of common stock on 12/15/2025 in a transaction coded “A” for acquisition at a price of $1,062.19 per share. After this transaction, he beneficially owned 16,741.37 shares held directly.
The shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following Luciano’s separation from service with the company.
Eli Lilly & Co director Mary Lynne Hedley reported acquiring 9.336 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, at her election these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service.
After this transaction, she beneficially owned 2,252.694 shares of Eli Lilly common stock directly and 98 shares indirectly through a trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation. The units were valued at $1,062.19 each under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after his separation from service.
After this transaction, Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.
Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.062 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, these shares were credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in shares of common stock after he separates from service as a director.
After this transaction, Alvarez beneficially owned 55,467.718 shares of Eli Lilly common stock directly and 758 shares indirectly through a trust, with the indirect ownership reported only to the extent of his pecuniary interest.
Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.
The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.
Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.
The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.
Eli Lilly & Co. (LLY) director Lilly Endowment Inc. reported open-market sales of Eli Lilly common stock on 11/25/2025. The Endowment sold 5,043 shares at a weighted average price of $1,108.71, 9,249 shares at a weighted average price of $1,109.449, and 1,340 shares at a weighted average price of $1,110.527, for a total of 15,632 shares sold.
After these transactions, Lilly Endowment Inc. beneficially owned 92,196,978 shares of Eli Lilly common stock, held directly. The prices reported reflect multiple trades within narrow ranges for each block of shares. This filing is identified as the second of two Forms 4 filed by the reporting person on the same date, covering transactions numbered 31 through 33 of 33 total transactions.
Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including $1,073.735 and $1,107.48 per share, and footnotes detailing underlying trade ranges from $1,073.78 to $1,107.95. After completing these reported sales, Lilly Endowment Inc. beneficially owned 92,212,610 shares of Eli Lilly common stock, held directly. This filing is identified as the first of two Forms 4 filed the same day, covering transactions numbered 1 through 30 of 33 total.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co (LLY), reported multiple sales of Eli Lilly common stock on 11/24/2025. The largest block shown was 120,016 shares sold at a weighted average price of $1,068.175 per share, with additional smaller sales the same day at weighted average prices between about $1,069.477 and $1,073.597 per share.
After these transactions, Lilly Endowment directly beneficially owned 92,359,671 shares of Eli Lilly common stock. The prices reported are weighted averages for multiple trades within narrow price ranges, and the reporting person has indicated a willingness to provide detailed trade breakdowns upon request.
Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.
The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.
Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.
The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.